Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells

Martin C. Pearce, John T. Gamble, Prasad R. Kopparapu, Edmond F. O'Donnell, Monica J. Mueller, Hyo Sang Jang, Julie A. Greenwood, Arnold C. Satterthwait, Robert L. Tanguay, Xiao Kun Zhang, Siva Kumar Kolluri

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Resistance to chemotherapy is a major cause of treatment failure and poor overall survival in patients with lung cancer. Identification of molecular targets present in resistant cancer cells is essential for addressing therapeutic resistance and prolonging lung cancer patient survival. Members of the B-cell lymphoma 2 (Bcl-2) family of proteins are associated with chemotherapeutic resistance. In this study, we found that pro-survival protein Bcl-2 is upregulated in paclitaxel resistant cells, potentially contributing to chemotherapy resistance. To exploit the increase in Bcl-2 expression for targeting therapy resistance, we investigated the effects of a peptide derived from the nuclear receptor Nur77 that converts Bcl-2 from an anti-apoptotic protein to a pro-apoptotic protein. The Nur77 derived peptide preferentially induced apoptosis in paclitaxel-resistant cancer cells with high expression of Bcl-2. This peptide also induced apoptosis of multidrug resistant H69AR lung cancer cells that express Bcl-2 and inhibited their growth in 3D spheroids. The Nur77 peptide strongly suppressed the growth of paclitaxel-resistant lung cancer cells in a zebrafish xenograft tumor model. Taken together, our data supports a new strategy for treating lung cancers that acquire resistance to chemotherapy through overexpression of Bcl-2.

Original languageEnglish (US)
Pages (from-to)26072-26085
Number of pages14
JournalOncotarget
Volume9
Issue number40
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

B-Cell Lymphoma
Lung Neoplasms
Apoptosis
Peptides
Growth
Paclitaxel
Neoplasms
Apoptosis Regulatory Proteins
Drug Therapy
Survival
Zebrafish
Cytoplasmic and Nuclear Receptors
Treatment Failure
Heterografts
Therapeutics
Proteins

Keywords

  • Bcl-2
  • Chemoresistance
  • Lung cancer
  • NuBCP-9
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology

Cite this

Pearce, M. C., Gamble, J. T., Kopparapu, P. R., O'Donnell, E. F., Mueller, M. J., Jang, H. S., ... Kolluri, S. K. (2018). Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells. Oncotarget, 9(40), 26072-26085. https://doi.org/10.18632/oncotarget.25437

Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells. / Pearce, Martin C.; Gamble, John T.; Kopparapu, Prasad R.; O'Donnell, Edmond F.; Mueller, Monica J.; Jang, Hyo Sang; Greenwood, Julie A.; Satterthwait, Arnold C.; Tanguay, Robert L.; Zhang, Xiao Kun; Kolluri, Siva Kumar.

In: Oncotarget, Vol. 9, No. 40, 01.01.2018, p. 26072-26085.

Research output: Contribution to journalArticle

Pearce, MC, Gamble, JT, Kopparapu, PR, O'Donnell, EF, Mueller, MJ, Jang, HS, Greenwood, JA, Satterthwait, AC, Tanguay, RL, Zhang, XK & Kolluri, SK 2018, 'Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells', Oncotarget, vol. 9, no. 40, pp. 26072-26085. https://doi.org/10.18632/oncotarget.25437
Pearce, Martin C. ; Gamble, John T. ; Kopparapu, Prasad R. ; O'Donnell, Edmond F. ; Mueller, Monica J. ; Jang, Hyo Sang ; Greenwood, Julie A. ; Satterthwait, Arnold C. ; Tanguay, Robert L. ; Zhang, Xiao Kun ; Kolluri, Siva Kumar. / Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells. In: Oncotarget. 2018 ; Vol. 9, No. 40. pp. 26072-26085.
@article{3487169749814ee3a4a53ff9113e5594,
title = "Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells",
abstract = "Resistance to chemotherapy is a major cause of treatment failure and poor overall survival in patients with lung cancer. Identification of molecular targets present in resistant cancer cells is essential for addressing therapeutic resistance and prolonging lung cancer patient survival. Members of the B-cell lymphoma 2 (Bcl-2) family of proteins are associated with chemotherapeutic resistance. In this study, we found that pro-survival protein Bcl-2 is upregulated in paclitaxel resistant cells, potentially contributing to chemotherapy resistance. To exploit the increase in Bcl-2 expression for targeting therapy resistance, we investigated the effects of a peptide derived from the nuclear receptor Nur77 that converts Bcl-2 from an anti-apoptotic protein to a pro-apoptotic protein. The Nur77 derived peptide preferentially induced apoptosis in paclitaxel-resistant cancer cells with high expression of Bcl-2. This peptide also induced apoptosis of multidrug resistant H69AR lung cancer cells that express Bcl-2 and inhibited their growth in 3D spheroids. The Nur77 peptide strongly suppressed the growth of paclitaxel-resistant lung cancer cells in a zebrafish xenograft tumor model. Taken together, our data supports a new strategy for treating lung cancers that acquire resistance to chemotherapy through overexpression of Bcl-2.",
keywords = "Bcl-2, Chemoresistance, Lung cancer, NuBCP-9, Paclitaxel",
author = "Pearce, {Martin C.} and Gamble, {John T.} and Kopparapu, {Prasad R.} and O'Donnell, {Edmond F.} and Mueller, {Monica J.} and Jang, {Hyo Sang} and Greenwood, {Julie A.} and Satterthwait, {Arnold C.} and Tanguay, {Robert L.} and Zhang, {Xiao Kun} and Kolluri, {Siva Kumar}",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.25437",
language = "English (US)",
volume = "9",
pages = "26072--26085",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "40",

}

TY - JOUR

T1 - Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells

AU - Pearce, Martin C.

AU - Gamble, John T.

AU - Kopparapu, Prasad R.

AU - O'Donnell, Edmond F.

AU - Mueller, Monica J.

AU - Jang, Hyo Sang

AU - Greenwood, Julie A.

AU - Satterthwait, Arnold C.

AU - Tanguay, Robert L.

AU - Zhang, Xiao Kun

AU - Kolluri, Siva Kumar

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Resistance to chemotherapy is a major cause of treatment failure and poor overall survival in patients with lung cancer. Identification of molecular targets present in resistant cancer cells is essential for addressing therapeutic resistance and prolonging lung cancer patient survival. Members of the B-cell lymphoma 2 (Bcl-2) family of proteins are associated with chemotherapeutic resistance. In this study, we found that pro-survival protein Bcl-2 is upregulated in paclitaxel resistant cells, potentially contributing to chemotherapy resistance. To exploit the increase in Bcl-2 expression for targeting therapy resistance, we investigated the effects of a peptide derived from the nuclear receptor Nur77 that converts Bcl-2 from an anti-apoptotic protein to a pro-apoptotic protein. The Nur77 derived peptide preferentially induced apoptosis in paclitaxel-resistant cancer cells with high expression of Bcl-2. This peptide also induced apoptosis of multidrug resistant H69AR lung cancer cells that express Bcl-2 and inhibited their growth in 3D spheroids. The Nur77 peptide strongly suppressed the growth of paclitaxel-resistant lung cancer cells in a zebrafish xenograft tumor model. Taken together, our data supports a new strategy for treating lung cancers that acquire resistance to chemotherapy through overexpression of Bcl-2.

AB - Resistance to chemotherapy is a major cause of treatment failure and poor overall survival in patients with lung cancer. Identification of molecular targets present in resistant cancer cells is essential for addressing therapeutic resistance and prolonging lung cancer patient survival. Members of the B-cell lymphoma 2 (Bcl-2) family of proteins are associated with chemotherapeutic resistance. In this study, we found that pro-survival protein Bcl-2 is upregulated in paclitaxel resistant cells, potentially contributing to chemotherapy resistance. To exploit the increase in Bcl-2 expression for targeting therapy resistance, we investigated the effects of a peptide derived from the nuclear receptor Nur77 that converts Bcl-2 from an anti-apoptotic protein to a pro-apoptotic protein. The Nur77 derived peptide preferentially induced apoptosis in paclitaxel-resistant cancer cells with high expression of Bcl-2. This peptide also induced apoptosis of multidrug resistant H69AR lung cancer cells that express Bcl-2 and inhibited their growth in 3D spheroids. The Nur77 peptide strongly suppressed the growth of paclitaxel-resistant lung cancer cells in a zebrafish xenograft tumor model. Taken together, our data supports a new strategy for treating lung cancers that acquire resistance to chemotherapy through overexpression of Bcl-2.

KW - Bcl-2

KW - Chemoresistance

KW - Lung cancer

KW - NuBCP-9

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=85047446111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047446111&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25437

DO - 10.18632/oncotarget.25437

M3 - Article

AN - SCOPUS:85047446111

VL - 9

SP - 26072

EP - 26085

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 40

ER -